A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination

Clinical Infectious Diseases

Volumn 59, Issue 9, 2014, Pages 1216-1221

  Bijlsma, Merijn W ^a   Brouwer, Matthijs C ^a   Spanjaard, Lodewijk ^a   Beek, Diederik Van De ^a   Ende, Arie Van Der ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

herd protection; Meningococcal infections; serogroup C meningococcal conjugate vaccine

Indexed keywords

MENINGOCOCCAL SEROGROUP C CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG; SEROGROUP C MENINGOCOCCAL CONJUGATE VACCINE;

ADOLESCENT; ADULT; AGED; BACTERIAL COLONIZATION; BACTERIAL IMMUNITY; BACTERIUM ISOLATE; CHILD; CLINICAL OBSERVATION; CLONAL VARIATION; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; GROUPS BY AGE; HERD IMMUNITY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; MULTILOCUS SEQUENCE TYPING; NASOPHARYNX; NEISSERIA MENINGITIDIS; NETHERLANDS; REVIEW; SEROTYPE; VACCINATION; CLASSIFICATION; COHORT ANALYSIS; GENETICS; IMMUNOLOGY; INFANT; MENINGOCOCCAL INFECTIONS; MICROBIOLOGY; MIDDLE AGED; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; IMMUNITY, HERD; INCIDENCE; INFANT; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MIDDLE AGED; MULTILOCUS SEQUENCE TYPING; NEISSERIA MENINGITIDIS, SEROGROUP C; NETHERLANDS; YOUNG ADULT;

EID: 84913588628     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu601     Document Type: Review

References (28)

1. Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev 2007; 31:101-7.
2. de Vries M, Dankert J, Ruijs H, Timen A, de Greeff S, de Melker H. Universal vaccination against group C meningococci and pneumococci; advice from the Health Council of the Netherlands. Ned Tijdschr Geneeskd 2002; 146:1562-3.
3. de Greeff SC, de Melker HE, Spanjaard L, Schouls LM, van Deuren A. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J 2006; 25:79-80.
4. Kaaijk P, van der Ende A, Berbers G, van den Dobbelsteen GP, Rots NY. Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands. BMC Infect Dis 2012; 12:35.
5. Maiden MC, Ibarz-Pavon AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008; 197:737-43.
6. Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 2009; 8:851-61.
7. Daugla DM, Gami JP, Gamougam K, et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. Lancet 2014; 383:40-7.
8. Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010; 17:840-7.
9. de Voer RM, Mollema L, Schepp RM, et al. Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal C conjugate vaccine. PLoS One 2010; 5:e12144.
10. Ishola DA Jr, Borrow R, Findlow H, Findlow J, Trotter C, Ramsay ME. Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction. Clin Vaccine Immunol 2012; 19:1126-30.
11. Caugant DA. Genetics and evolution of Neisseria meningitidis: importance for the epidemiology of meningococcal disease. Infect Genet Evol 2008; 8:558-65.
12. Jolley KA, Brehony C, Maiden MC. Molecular typing of meningococci: recommendations for target choice and nomenclature. FEMS Microbiol Rev 2007; 31:89-96.
13. Claus H, Maiden MC,Wilson DJ, et al. Genetic analysis of meningococci carried by children and young adults. J Infect Dis 2005; 191:1263-71.
14. Spanjaard L, Bol P, Ekker W, Zanen HC. The incidence of bacterial meningitis in the Netherlands-a comparison of three registration systems, 1977-1982. J Infect 1985; 11:259-68.
15. van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004; 351:1849-59.
16. Ouchterlony O. Antigen-antibody reactions in gels. Acta Pathol Microbiol Scand 1949; 26:507-15.
17. Maiden MC, Bygraves JA, Feil E, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA 1998; 95:3140-5.
18. de Greeff SC, de Melker HE, Spanjaard L, van den Hof S, Dankert J. The first effect of the national vaccination campaign against meningococcal-C disease: a rapid and sharp decrease in the number of patients. Ned Tijdschr Geneeskd 2003; 147:1132-5.
19. Fine P, Eames K, Heymann DL. "Herd immunity": a rough guide. Clin Infect Dis 2011; 52:911-6.
20. Clemens J, Shin S, Ali M. New approaches to the assessment of vaccine herd protection in clinical trials. Lancet Infect Dis 2011; 11:482-7.
21. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001; 20(suppl 1):S58-67.
22. Muhlemann K, Weiss NS. Can herd immunity influence the assessment of vaccine efficacy in nonrandomized studies? Am J Public Health 1997; 87:113-4.
23. Hayes RJ, Alexander ND, Bennett S, Cousens SN. Design and analysis issues in cluster-randomized trials of interventions against infectious diseases. Stat Methods Med Res 2000; 9:95-116.
24. Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:853-61.
25. Pollard AJ, Frasch C. Development of natural immunity to Neisseria meningitidis. Vaccine 2001; 19:1327-46.
26. Griffin MR, Walker FJ, Iwane MK, Weinberg GA, Staat MA, Erdman DD. Epidemiology of respiratory infections in young children: insights from the new vaccine surveillance network. Pediatr Infect Dis J 2004; 23:S188-92.
27. Harrison LH, Shutt KA, Schmink SE, et al. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era-United States, 2000-2005. J Infect Dis 2010; 201:1208-24.
28. Bijlsma MW, Bekker V, Brouwer MC, Spanjaard L, van de Beek D, van der Ende A. Epidemiology of invasive meningococcal disease from 1960 through 2012: a study of national surveillance data from the Netherlands. Lancet Infect Dis 2014; doi:10.1016/S1473-3099(14)70806-0.